image
Shattuck Labs, Inc. STTK
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 0.733
-9.84 %
$ 35.1 M
Market Cap
-0.49
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one STTK stock under the worst case scenario is HIDDEN Compared to the current market price of 0.733 USD, Shattuck Labs, Inc. is HIDDEN

STTK Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one STTK stock under the base case scenario is HIDDEN Compared to the current market price of 0.733 USD, Shattuck Labs, Inc. is HIDDEN

STTK Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one STTK stock under the best case scenario is HIDDEN Compared to the current market price of 0.733 USD, Shattuck Labs, Inc. is HIDDEN

STTK Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart STTK

image
1M -68%
6M -75%
1Y -1170%
3Y -438%
5Y --%
All
$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.615 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
1.66 M REVENUE
154.14%
Growth Rates
1Year 154.14%
3Years -44.95%
5Years -40.62%
7Years 0.00%
10Years 0.00%
-92 M OPERATING INCOME
11.01%
Growth Rates
1Year 11.01%
3Years -35.54%
5Years -71.78%
7Years 0.00%
10Years 0.00%
-87.3 M NET INCOME
14.37%
Growth Rates
1Year 14.37%
3Years -33.61%
5Years -63.87%
7Years 0.00%
10Years 0.00%
-81.2 M OPERATING CASH FLOW
14.04%
Growth Rates
1Year 14.04%
3Years -34.13%
5Years -63.73%
7Years 0.00%
10Years 0.00%
111 M INVESTING CASH FLOW
124.24%
Growth Rates
1Year 124.24%
3Years 40.23%
5Years 41.66%
7Years 0.00%
10Years 0.00%
48.6 M FINANCING CASH FLOW
28330.41%
Growth Rates
1Year 28330.41%
3Years -47.23%
5Years 6.70%
7Years 0.00%
10Years 0.00%
3 M REVENUE
86.26%
Growth Rates
1Year 154.14%
3Years -44.95%
5Years -40.62%
7Years 0.00%
10Years 0.00%
-17.9 M OPERATING INCOME
21.96%
Growth Rates
1Year 11.01%
3Years -35.54%
5Years -71.78%
7Years 0.00%
10Years 0.00%
-16.7 M NET INCOME
22.63%
Growth Rates
1Year 14.37%
3Years -33.61%
5Years -63.87%
7Years 0.00%
10Years 0.00%
-16.1 M OPERATING CASH FLOW
-47.15%
Growth Rates
1Year 14.04%
3Years -34.13%
5Years -63.73%
7Years 0.00%
10Years 0.00%
-821 K INVESTING CASH FLOW
84.84%
Growth Rates
1Year 124.24%
3Years 40.23%
5Years 41.66%
7Years 0.00%
10Years 0.00%
23 K FINANCING CASH FLOW
-97.75%
Growth Rates
1Year 28330.41%
3Years -47.23%
5Years 6.70%
7Years 0.00%
10Years 0.00%
Balance Sheet Shattuck Labs, Inc.
image
Current Assets 143 M
Cash & Short-Term Investments 131 M
Receivables 0
Other Current Assets 12.6 M
Non-Current Assets 16.3 M
Long-Term Investments 0
PP&E 13.8 M
Other Non-Current Assets 2.54 M
81.86 %7.89 %8.65 %Total Assets$159.6m
Current Liabilities 11.5 M
Accounts Payable 1.59 M
Short-Term Debt 796 K
Other Current Liabilities 9.07 M
Non-Current Liabilities 3.41 M
Long-Term Debt 3.41 M
Other Non-Current Liabilities 0
10.68 %5.36 %61.04 %22.92 %Total Liabilities$14.9m
EFFICIENCY
Earnings Waterfall Shattuck Labs, Inc.
image
Revenue 1.66 M
Cost Of Revenue 4.04 M
Gross Profit -2.38 M
Operating Expenses 93.6 M
Operating Income -92 M
Other Expenses -4.66 M
Net Income -87.3 M
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)(100m)(100m)2m(4m)(2m)(94m)(92m)5m(87m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-143.93% GROSS MARGIN
-143.93%
Averages
1Year -143.93%
3Years -155.39%
5Years -187.36%
7Years 0.00%
10Years 0.00%
-5549.61% OPERATING MARGIN
-5549.61%
Averages
1Year -5549.61%
3Years -7182.81%
5Years -4434.74%
7Years 0.00%
10Years 0.00%
-5268.44% NET MARGIN
-5268.44%
Averages
1Year -5268.44%
3Years -6946.55%
5Years -4287.58%
7Years 0.00%
10Years 0.00%
-60.33% ROE
-60.33%
Averages
1Year -60.33%
3Years -44.58%
5Years -15.21%
7Years 0.00%
10Years 0.00%
-54.71% ROA
-54.71%
Averages
1Year -54.71%
3Years -39.51%
5Years -36.36%
7Years 0.00%
10Years 0.00%
-61.75% ROIC
-61.75%
Averages
1Year -61.75%
3Years -44.78%
5Years -49.00%
7Years 0.00%
10Years 0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Shattuck Labs, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)201920192020202020212021202220222023202320242024
Net Income -87.3 M
Depreciation & Amortization 4.04 M
Capital Expenditures -407 K
Stock-Based Compensation 6.94 M
Change in Working Capital -4.1 M
Others 718 K
Free Cash Flow -81.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Shattuck Labs, Inc.
image
Wall Street analysts predict an average 1-year price target for STTK of $12 , with forecasts ranging from a low of $8 to a high of $16 .
STTK Lowest Price Target Wall Street Target
8 USD 991.41%
STTK Average Price Target Wall Street Target
12 USD 1537.11%
STTK Highest Price Target Wall Street Target
16 USD 2082.81%
Price
Max Price Target
Min Price Target
Average Price Target
16161414121210108866442200May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Shattuck Labs, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
167 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
211 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
82.8 K USD 2
9-12 MONTHS
7. News
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 – SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study –  – SL-325 receptor occupancy (RO) and pharmacokinetic (PK) profile observed suggestive of extended dosing intervals; IND filing expected in the third quarter of 2025 –  AUSTIN, TX & DURHAM, NC, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced positive preclinical data from an IND-enabling GLP toxicology study of SL-325 in non-human primates (NHP). These data were featured in a digital oral presentation on February 20, 2025, during the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 in Berlin, Germany. globenewswire.com - 1 month ago
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will feature results from the IND-enabling toxicology studies of SL-325, a first-in-class DR3 blocking antibody, in non-human primates. globenewswire.com - 1 month ago
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn's and Colitis Congress being held in San Francisco, California from February 6–8, 2025. globenewswire.com - 2 months ago
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California on January 13-16, 2025. globenewswire.com - 2 months ago
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced a corporate update and highlighted upcoming key milestones anticipated in 2025. globenewswire.com - 3 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 4 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 4 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 4 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 4 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 4 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 4 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK NEW YORK CITY, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accesswire.com - 5 months ago
8. Profile Summary

Shattuck Labs, Inc. STTK

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 35.1 M
Dividend Yield 0.00%
Description Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Contact 500 West 5th Street, Austin, TX, 78703 https://www.shattucklabs.com
IPO Date Oct. 9, 2020
Employees 75
Officers Ms. Casi DeYoung Chief Business Officer Mr. Conor Richardson CPA Vice President of Investor Relations Mr. Andrew R. Neill M.B.A. Chief Financial Officer Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. Chief Medical Officer Dr. Abhinav A. Shukla Ph.D. Chief Technical Officer Dr. Thomas Lampkin Pharm.D. Senior Vice President of Regulatory Affairs Dr. Taylor H. Schreiber M.D., Ph.D. Co-Founder, Chief Executive Officer & Director Dr. Stephen Stout J.D., Ph.D. General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer Mr. George Fromm Ph.D. Co-Chief Scientific Officer Mr. Suresh de Silva Ph.D. Co-Chief Scientific Officer